The EP300 antibody targets the EP300 protein, a multifunctional transcriptional coactivator encoded by the EP300 gene in humans. EP300. also known as p300. functions as a histone acetyltransferase (HAT), playing a critical role in chromatin remodeling and transcriptional regulation. It interacts with numerous transcription factors, including CREB-binding protein (CBP), with which it shares structural and functional homology, to modulate gene expression involved in cell proliferation, differentiation, apoptosis, and DNA repair. Dysregulation of EP300 is implicated in various cancers, neurological disorders, and developmental syndromes such as Rubinstein-Taybi syndrome.
EP300 antibodies are widely used in research to study protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP). These antibodies help elucidate EP300's role in signaling pathways (e.g., Wnt/β-catenin, p53) and epigenetic mechanisms. Challenges include ensuring specificity due to its high similarity with CBP and detecting post-translational modifications.
Validation of EP300 antibodies typically involves knockout cell lines or siRNA knockdown to confirm target specificity. Commercial antibodies are available in monoclonal and polyclonal forms, often validated for multiple applications. Reliable EP300 antibodies are essential for advancing studies in cancer biology, epigenetics, and therapeutic development targeting HAT activity or protein-protein interactions.